Sanjay Popat

Dec 5, 2024 | nature.com | Sanjay Popat |James B. Spicer |Allan Hackshaw

AbstractHere we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring. TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged ≥18 were treated with daily oral afatinib (40 mg) until disease progression or unacceptable toxicity.

Sep 26, 2024 | ejcancer.com | Sanjay Popat |Mark Ratain

Get full text accessLog in, subscribe or purchase for full access. References1. Skoulidis, F. ∙ Li, B.T. ∙ Dy, G.K. ... Sotorasib for Lung Cancers with KRAS p.G12C MutationN Engl J Med. 2021; 384:2371-23812. de Langen, A.J. ∙ Johnson, M.L. ∙ Mazieres, J. ... Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401:733-7463. FDA.

Sep 16, 2024 | onclive.com | Sanjay Popat

CommentaryVideoSeptember 16, 2024Author(s):Fact checked by:Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Nov 29, 2023 | medscape.co.uk | Sanjay Popat

Patients with limited stage SCLC (stage I–III eligible for treatment of curative intent) Patients with R1–R2 resection or positive mediastinal lymph nodes (N2) Adjuvant chemotherapy and radiotherapy, preferably concurrently Limited stage (stage I–III) Limited stage (stage I–III) if cisplatin is contraindicated Treatment option to prevent haematological toxicity Patients with T1–4N0–3M0 tumours and a good PS (0–1) Concurrent chemotherapy and thoracic radiotherapy (45 Gy twice daily in 30...

Jul 12, 2023 | medscape.co.uk | Sanjay Popat

First-line Combinations for Advanced NSCLC Regardless of PD-(L)1 Status in Patients with PS 0–1 Without Contraindications for ICIs Use combinations of platinum-based ChT and anti-PD-(L)1 inhibitors in preference to platinum-based ChT Adjust treatment duration according to tolerability and clinical efficacy In most registered strategies, ICI treatment was limited to 2 years Non-squamous non-small cell carcinoma Pembrolizumab–pemetrexed–platinum Atezolizumab–bevacizumab–paclitaxel–carboplatin...